Sign in
CMMB Stock Price, Chart, Stats & News
Chemomab Therapeutics Ltd.
Save
9.36M
Market cap
–
Current P/E
12.94x
Forward P/E
CMMB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -65.21% |
ROE | -82.52% |
D/E | – |
Interest coverage ratio | – |
CMMB valuation
P/E | – |
P/S | – |
P/B | 0.93x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.06x |
EV multiple | -1.77x |
About
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Similar securities
Based on sector and market capitalization
Report issue